Concepedia

Publication | Open Access

Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma

DOIFull Paper Access

74

Citations

25

References

2020

Year

Wei Sang, Ming Shi, Jing‐Jing Yang, Jiang Cao, Linyan Xu, Dongmei Yan, Meixue Yao, Hui Liu, Weidong Li, Bing Zhang,
Cancer Medicine

Abstract

Coadministration of anti-CD19 and CD20 CAR-T cells therapy for DLBCL is feasible with manageable toxicity. Cytokine markers are related to toxicity and SUVmax could predict efficacy. This trial was registered at www.clinicaltrials.gov as NCT03207178.

References

YearCitations

Page 1